Market Newsdesk

WOBURN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a provider of cloud-based digital experience software, has announced a European home and hardware company has selected Celebros Search as their site search and merchandising solution for their online store.

The company operates both online and offline and is a one-stop-shop for building, home & garden needs. Established in 1960, they are one of the largest independent home & hardware stores in northern Europe.

The company recently launched a new eCommerce website with the abcommerce platform, a long-time partner of Bridgeline, with a large selection of categories and products, and needed the enhanced functionality of Celebros to help them attain their goals to drive new traffic, increase conversions, and improve average order sizes.

Celebros was selected for its natural language processing (NLP) site search, with machine learning and AI capabilities. Using these advanced technologies, Celebros can map out the customer’s journey, including the complex keywords they input, to improve the accuracy of their search results and recommend products they may want to buy.

Celebros was also selected for its AutoComplete functionality. This feature can self-learn and show relevant search result recommendations based on the letters typed into the search box.

Ari Kahn, Bridgeline Digital’s CEO, says, “We’re excited to expand our European presence and work with our partners, such as abcommerce, to introduce our suite of eCommerce tools to retailers and eTailers.”

About Bridgeline Digital

Bridgeline Digital, The Digital Engagement Company, helps customers maximize the performance of their omni-channel digital experience from websites and intranets to online stores and campaigns. Bridgeline’s Unbound platform is a Digital Experience Platform (DXP) that deeply integrates Web Content Management, eCommerce, Marketing Automation, Site Search, Authenticated Portals, Social Media Management, Translation, Locator Pages and Web Analytics to help the goal of assisting marketers to help organizations deliver digital experiences that attract, engage, nurture and convert their customers across all channels and streamline business operations.  OrchestraCMS is the only content and digital experience platform built 100% native on Salesforce. OrchestraCMS helps Salesforce create digital experiences for their customers and partners; combining content with business data, processes and applications across multiply channels and device including Salesforce Communities, social media, portals, intranets, websites, applications and services.  Celebros Search is a commerce oriented, site search product that provides for Natural Language Processing with artificial intelligence (AI) to present very relevant search results in seven languages.  Headquartered in Woburn, MA., Bridgeline customers range from small- and medium-sized organizations to Fortune 1000 companies. To learn more, please visit www.bridgeline.com or call (800) 603-9936.

Contact:
Jeremy LaDuque
EVP of Marketing
Bridgeline Digital, Inc.
[email protected]

Only Verizon customers have access to
the robust network architecture of our 4G foundational network,
the most technologically advanced 5G Nationwide network and 5G Ultra Wideband, the world’s fastest.

What you need to know:

• 24 million customers throughout Central Texas, Tulsa, OK, Upstate New York, and the New England area now have access to Verizon’s 5G Nationwide service for no added cost, bringing the total customers with access to the most advanced nationwide service to more than 230 million in over 2,700 cities.
• Customers in parts of Tampa, St. Petersburg, Albuquerque and Durham now have access to the unprecedented performance of 5G Ultra Wideband, available in 61 cities, 48 stadiums and arenas and seven airports.

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) — Today an additional 24 million customers have access to Verizon’s technologically advanced 5G nationwide network for no added cost.^* Verizon announced continued expansion of its 5G Nationwide service to millions more customers throughout Central Texas, Tulsa, OK, Upstate New York, and the New England area, bringing the total to 230 million people able to access Verizon’s 5G capabilities and benefits in over 2,700 cities.

Additionally, Verizon has expanded access to its 5G Ultra Wideband network to customers in parts of Tampa, St Petersburg, Albuquerque and Durham, giving them access to the unprecedented speeds and capabilities of the world’s fastest 5G.^** Customers in 61 cities can now experience ultra-fast wireless speeds, allowing them to download and stream movies and TV shows in seconds, videoconference and collaborate remotely in near real time, and take advantage of new immersive customer experiences never before available wirelessly. Enterprise customers in these markets now have access to the technology that can dramatically accelerate their digital transformation, revolutionizing how they interact with their customers, track inventory, manage operations and engage with their workforce.

The most advanced 5G Nationwide network

Verizon’s nationwide network is built with the most advanced technologies available in the industry.

• The underlying network architecture is built on a cloud-native containerized architecture, similar to the IP-based architecture used by the most notable global tech companies, which can allow for unprecedented levels of operational automation, flexibility and adaptability.
• Verizon’s 5G Nationwide employs Dynamic Spectrum Sharing technology, which allows 5G service to run simultaneously with 4G LTE on multiple spectrum bands. This new technology allows Verizon to dynamically use its full portfolio of current spectrum resources to serve both 4G and 5G customers, maximizing their experience on the Verizon network. Customers can use Verizon’s network in a variety of ways — from virtual learning to real-time gaming — that requires the ability to allocate spectrum resources in real time.
• And much of the newest expansion of Verizon’s Nationwide 5G network uses virtualization all the way to cell sites at the edge of the network. Virtualizing the cell sites and functions, like the virtualization work previously completed in the core of the network, decouples software and hardware functionality enabling the network to be built on general purpose hardware. Using Common Off-The-Shelf (COTS) hardware leads to greater flexibility and agility in the introduction of new products and services. Instead of adding or upgrading single-purpose hardware, the move to a cloud native, container-based virtualized architecture leads to greater flexibility, faster delivery of services, greater scalability, and improved cost efficiency in networks. This virtualization will also lower the barrier to entry for new vendors in the ecosystem. New entrants can accelerate innovation, reduce operating costs, and lay the groundwork for flexible network and cloud infrastructure closer to the customer, eventually leading to single digit latency. Key 5G use cases focused on providing the best, most efficient network for customers, will heavily rely on the programmability of virtualized networks.

The world’s fastest 5G network

Using advanced technology called Carrier Aggregation, Verizon’s 5G Ultra Wideband network is reaching 4 Gbps peak speeds in some locations. This technology combines multiple channels of spectrum to provide greater efficiency for data sessions transmitting over the wireless network. Verizon combined eight separate channels of mmWave spectrum to achieve multi-gigabit speeds in parts of some cities. Using this technology, customers can see double the download speeds they have historically experienced on 5G Ultra Wideband, with peak speeds up to 4 Gbps possible in some locations. Customers will also see a boost in speeds with two carrier aggregation now available for uploads. Combined with Verizon’s vast quantity of available spectrum in mmWave, carrier aggregation allows customers on 5G Ultra Wideband to achieve unprecedented mobile speeds and brings the massive bandwidth available with mmWave spectrum to life.

Verizon’s award-winning 4G LTE Network

A distinct advantage in the deployment of 5G is having a robust, dense, and high-performing 4G LTE Advanced network. Verizon’s 5G network designs share many commonalities with its award-winning 4G LTE Advanced network. The underlying small cell, fiber and radio wave infrastructure of 4G LTE has created the solid technical foundation needed to build Verizon’s 5G networks right. And with Verizon’s award-winning 4G LTE performance, Verizon has been able to focus on building targeted mmWave services that bring a transformational experience, develop a technologically advanced 5G Nationwide network and consistently provide reliable, world-class service to customers using its 4G services.

“The technology found in both our 5G Ultrawideband and our 5G Nationwide networks reflects a massive, mulit-year innovation effort that modernizes our entire network with cutting edge capability,” said Kyle Malady, Chief Technology Officer of Verizon. “We believe our customers deserve 5G built right, so as we have with technology innovation and advancements throughout our history, we are committed to providing the most advanced technology with the most capabilities that will support the new 5G ecosystem and developing solutions long into the future.”

Specific 5G coverage can be found here https://www.verizon.com/coverage-map/.

* Nationwide 5G service available for no added cost on Verizon’s unlimited plans. Plan details can be found at www.Verizon.com/plans

** Global claim from May 2020, based on Opensignal independent analysis of mobile measurements recorded during the period January 31 – April 30, 2020 © 2020 Opensignal Limited

Media contact:

Karen Schulz
864.561.1527
[email protected] 

ATLANTA, Dec. 17, 2020 (GLOBE NEWSWIRE) — Blue Ridge, a leader in supply chain planning and pricing solutions, today announced a partnership with Affiliated Distributors (AD) to deliver its Supply Chain Planning solutions to its membership of independent distributors and best-in-class HVACR, plumbing, electrical and industrial suppliers across North America. Blue Ridge will be the exclusive provider of Supply Chain Planning and Sales & Operations Planning (S&OP) solutions for AD through the end of 2021.

AD is a member-owned organization with annual sales of $46 billion across nine industries and three countries. With more than 5,000 branches from 800-plus independently owned members, AD is North America’s largest marketing/buying group for construction and industrial supplies. In 2018, Frost & Sullivan recognized Blue Ridge as the Best Cloud-Native Supply Chain Planning Solution for Distributors.

“Blue Ridge has a tremendous track record for serving the unique supply chain planning needs of the distribution industry,” said David Hons, AD director of procurement. “Blue Ridge’s solutions are cloud-based and purpose-built for distributors, solving many of the industry’s key inventory planning challenges like seasonal, intermittent and slow-moving items.”

Blue Ridge’s cloud-native Supply Chain Planning (SCP) solution fully optimizes distributor inventory levels for both profit and desired service levels to the end customer. The solution automatically adapts to market trends and alerts users to suggested purchase order quantities, transfer orders, and demand shifts based on the latest data. Blue Ridge Integrated Business Planning (IBP) is a next-generation S&OP solution that synchronizes revenue, demand supply and financial plans to craft one, consensus operational plan that ensures accountability across functional silos of the business.

In February, Blue Ridge released the 2020 State of Wholesale Distribution Supply Chain Report, which revealed a clear market need for solutions that streamline forecasting processes and reduce uncertainty. The Company also held a webinar for HVAC and Hardgoods distributors in November 2020 that shared three “war stories” of distributors – the metrics they achieved and how they used these technologies to get a handle on overstock, stockouts and inventory planning efficiency. The replay is available here.

“AD is the organization which all distributors look to for guidance in finding the best technology solutions to improve revenue and increase efficiency across an organization,” said Jeff Jenkins, Blue Ridge chief revenue officer. “The Blue Ridge platform takes into account unpredictable customer behavior, enabling these companies to make a comprehensive market assessment, accurately predicting customer demand with more certainty and speed far beyond what an ERP can do.”

About Blue Ridge

Blue Ridge Supply Chain Planning and Price Optimization solutions empower distributors and retailers to tap into undiscovered margin through enterprise-wide inventory intelligence, automation and synchronization. Blue Ridge uniquely combines demand forecasting with pricing strategy, so that businesses can proactively understand the unpredictable and allocate the right inventory, right-priced across the entire mix, to accelerate top- and bottom-line results. In a world where the only constant is change, Blue Ridge provides more certainty, more speed and more assurance, so companies can see the why behind the buy and respond faster to the unexpected. That’s why major retailers and distributors rely on Blue Ridge for a more foreseeable future. For more information, go to www.blueridgeglobal.com.

Media Contact:

Will Haraway
Backbeat Marketing
[email protected]
404.593.8320

MOORESTOWN, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces today it has entered into a partnership with Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions. Through this initiative, Physiomics’ personalized docetaxel model will be integrated into TRHC’s market-leading precision dosing solution, DoseMeRx®. Both parties expect positive feedback from this initial trial with the next step being a commercial agreement.

Cancer remains one of the leading causes of death in developed countries and one of the most significant areas of spend for health systems. There are many effective cancer drugs; but, it is well established that, given the same dose, variations between individuals mean that different amounts of drug reach their tumours.

Using measurements of the amount of drug in a patient’s blood to guide what dose they should receive has been shown to improve efficacy and reduce side effects. The tests, however, are difficult to obtain in oncology because they are expensive and not standardized. Physiomics’ personalized dosing models currently rely only on inexpensive, standard blood tests that could help doctors and pharmacists in making decisions about the dose of cancer drugs for individual patients. TRHC’s DoseMeRx enables healthcare providers to optimize dosing and streamline operations, reduce adverse drug events, and decrease costs. The unique DoseMeRx platform incorporates Bayesian science to guide the safe and effective dosing of 42 different drugs.

Physiomics Chief Executive Officer, Jim Millen, MD, said, “Initially, we will focus on the drug docetaxel, which is commonly used to treat prostate, breast and other cancers. However, one of our goals is to establish how this could potentially be extended to apply to other drugs and cancer types. We partnered with TRHC because its DoseMeRx solution has been the leader in the personalized dosing field for several years, and they have demonstrated the ability to not only lead the science, but to make it accessible for those who can benefit from it. We look forward to the results of the trial and potentially entering into a revenue generating contract in due course.”

TRHC Chief Scientific Officer Jacques Turgeon, BPharm, PhD, added, “The focus of the collaboration is on delivering better outcomes for cancer patients. Incorporating this new science into DoseMeRx will enable clinicians to more effectively predict the timing of serious adverse effects, such as neutropenia, that are commonly observed in patients receiving chemotherapy. We have seen a great deal of success in infectious diseases through the use of DoseMeRx, and we are excited to expand this into oncology.”

Charles Cornish, TRHC’s Executive Vice President, Hospital Business Unit, said, “Through this partnership, we’re bringing together Physiomics’ expertise in oncology precision medication dosing with our experience in developing easy-to-use clinical decision support software. Combined with our network of healthcare providers throughout the United States and the world, this partnership will further support the safe use of these medications in clinical practice.”

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (TRHC) (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers, and other healthcare organizations. For more information, visit TRHC.com

About DoseMeRx

DoseMeRx® is a Tabula Rasa HealthCare solution and the first precision dosing software developed specifically for clinical practice. DoseMeRx’s clinical decision support solutions empower healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs, and improve patient outcomes. For more information, visit doseme-rx.com

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

Forward-Looking Statements

This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 2, 2020, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

TRHC Media Contact

Dianne Semingson
[email protected]
T: (215) 870-0829

TRHC Investor Contact

Frank Sparacino
[email protected]
T: (866) 648-2767

Physiomics plc

Dr Jim Millen, CEO
+44 (0)1865 784 980

JERSEY CITY, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $6.25 per share and accompanying warrants, and the pre-funded warrants are being sold at a public offering price of $6.249 per pre-funded warrant and accompanying warrants. The gross offering proceeds to SCYNEXIS from this offering are expected to be approximately $85.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants or warrants. All of the shares of common stock, pre-funded warrants and warrants are being offered by SCYNEXIS.

At closing, SCYNEXIS will issue 8,390,000 shares of its common stock and, pre-funded warrants to purchase 5,210,000 shares of common stock, and two series of warrants to purchase an aggregate of 13,600,000 additional shares of its common stock. The pre-funded warrants will be issued to certain purchasers who have elected to purchase them in lieu of shares of common stock in this offering, as those purchasers would otherwise have exceeded 19.99% (or such lesser percentage as required by the investor) beneficial ownership of our common stock immediately following the offering. The shares of common stock, pre-funded warrants and warrants will be issued separately. The Series 1 warrants to purchase up to 6,800,000 shares of common stock have a one-year term and an exercise price of $7.33 per share, and the Series 2 warrants to purchase up to 6,800,000 shares of common stock have a three-and-a-half-year term and an exercise price of $8.25 per share. The pre-funded warrants and the warrants in each series are exercisable immediately upon issuance. The warrants will be certified, and will be delivered to the investors by physical delivery following the closing. There is no established public trading market for the pre-funded warrants or the warrants, and SCYNEXIS does not expect a market to develop.

Guggenheim Securities, LLC and Cantor Fitzgerald & Co. are serving as joint book-running managers for the offering. Ladenburg Thalmann & Co. Inc. and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ: NHLD), are serving as co-lead managers for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, and WBB Securities LLC are serving as co-managers for the offering.

A shelf registration statement relating to the securities being sold in this offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 11, 2020, and was declared effective on October 1, 2020. The offering will be made only by means of a preliminary and final prospectus supplement and accompanying prospectus. When available, copies of the preliminary and final prospectus supplements and accompanying prospectus relating to the proposed public offering may be obtained by contacting: Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9658, or by email to [email protected]; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; mail: [email protected]. The final terms of the offering will be disclosed in the final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

In connection with the offering SCYNEXIS terminated its Controlled Equity Offering^SM Sales Agreements with Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements relating to SCYNEXIS’s expectations regarding the completion of the public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. SCYNEXIS cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that SCYNEXIS will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to SCYNEXIS and its business can be found in the “Risk Factors” section of SCYNEXIS’s Form 10-K for the year ended December 31, 2019, quarterly report on Form 10-Q for the quarterly period ended September 30, 2020, the preliminary prospectus supplement relating to the public offering and other filings with the SEC. There can be no assurance that SCYNEXIS will be able to complete the public offering on the anticipated terms, or at all. SCYNEXIS undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in SCYNEXIS’s expectations.

CONTACT

: 

Investor Relations

Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
[email protected]

Media Relations

Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
[email protected]

Berkeley Heights, New Jersey, Dec. 17, 2020 (GLOBE NEWSWIRE) — Axtria, a global leader in cloud software and data analytics for the life sciences commercial business, is honored to be Great Place to Work-Certified™. Certification is a significant achievement, and Axtria has doubled the reward with two designations. 2020 marks the first year Axtria’s US offices have applied and been certified. At the same time, Axtria’s India offices are counting 2020 as their third Certification (2018, 2019, and 2020).

Using validated employee feedback gathered with Great Place to Work’s rigorous, data-driven For All methodology, Certification confirms 7 out of 10 employees have a consistently positive experience at Axtria. Great Place to Work is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue and increased innovation.

“I am thrilled that Axtria has been Great Place to Work-Certified™ in both our US and India offices,” says Jassi Chadha, Axtria CEO and President. “This achievement substantiates our commitment to building an inclusive workplace culture based on our guiding core values. 2020 has been a challenging year, and I am extremely proud of how resilient our team has been throughout. Our employees have consistently shown that we are intrinsically connected, and I want to thank everyone for their relentless drive to succeed and delight our customers.”

“We congratulate Axtria on their Certification,” said Sarah Lewis-Kulin, Vice President of Best Workplace List Research at Great Place to Work. “Organizations that earn their employees’ trust create great workplace cultures that deliver outstanding business results.”

Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Great Place to Work helps organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees.

Great Place to Work® Certification would not have been possible without Axtrians’ consistent faith in the organization, its vision, and its values. Axtria’s leadership firmly believes that it is the people who differentiate Axtria from the competition. Building a culture that inspires trust and performance has, therefore, been the primary objective of Axtria. Getting Great Place To Work-Certified® is a testament to this effort.

Connect With Axtria:

• LinkedIn: https://www.linkedin.com/company/axtria/
• Facebook: https://www.facebook.com/AxtriaInc
• Twitter: https://twitter.com/Axtria
• Instagram: https://www.instagram.com/lifeataxtria/

About Axtria

Axtria is a global provider of cloud software and data analytics to the life sciences industry. Axtria helps life sciences companies transform the product commercialization journey to drive sales growth and improve healthcare outcomes for patients. Axtria is acutely aware that their work impacts millions of patients, and they lead passionately to improve patient lives.  

Since the company’s founding in 2010, technology innovation has been its winning differentiation. Axtria continues to leapfrog the competition with platforms that deploy artificial intelligence and machine learning.  Their cloud-based platforms – Axtria DataMAx™, Axtria InsightsMAx™, Axtria SalesIQ™, and Axtria MarketingIQ™ – enable customers to efficiently manage data, leverage data science to deliver insights for sales and marketing planning, and manage end-to-end commercial operations.  Axtria helps customers in the complete journey from data to insights to operations.  With customers in over 75 countries, Axtria is one of the biggest global commercial solutions providers in the life sciences industry.  Axtria continues to win industry recognition for growth and is featured in some of the most aspirational lists – Inc. 5000, Deloitte Technology Fast 500™, NJBIZ Fast 50, SmartCEO Future 50, Red Herring 100, and several other growth and technology awards.

Trademarks

Axtria, Axtria SalesIQ™, Axtria MarketingIQ™, Axtria InsightsMAx™, and Axtria DataMAx™ are registered trademarks of Axtria.  Other names may be trademarks of their respective owners.

About Great Place To Work®

To learn more, visit greatplacetowork.com, listen to the podcast Better by Great Place to Work, and read “A Great Place to Work for All.” Join the community on LinkedIn, Twitter, and Instagram.

Attachments

• Great Place to Work US 2020-12
• Great Place to Work – India

DALLAS, Dec. 17, 2020 (GLOBE NEWSWIRE) — Capital Southwest Corporation (“Capital Southwest”) (Nasdaq:CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, announced today that it recently supported the acquisition of Broad Sky Networks, Inc. (“Broad Sky”) by IntelliSite Corporation (“IntelliSite”), a portfolio company of DFW Capital Partners (“DFW”). Concurrent with the acquisition, IntelliSite created a new international, technology-focused, holding company EPIC IO Technology (“EPIC IO”) comprised of Broad Sky and IntelliSite as independent subsidiaries. CSWC supported the transaction with a first lien financing in Broad Sky and an equity co-investment in EPIC IO. Capital Southwest led the financing transaction and serves as the sole administrative agent on the credit facility.

“We are pleased to partner with DFW on its acquisition of Broad Sky. Through its existing investment in IntelliSite, DFW and the management team are building a robust technology services platform offering IoT solutions, wireless connectivity and AI services that is well-positioned for growth,” stated Douglas Kelley, Managing Director of Capital Southwest. Rachel Bazan, Vice President of Capital Southwest, said “Broad Sky’s recently launched Wireless Window™ platform positions the Company to continue to be the preeminent partner for customers’ wireless connectivity services.”

Founded in 2003, Broad Sky is a leading, single-source wireless provider for primary, temporary, failover, IoT, POTS replacement, satellite, and Future 5G across the U.S. and Canada. The company custom-engineers connectivity solutions for mid-market and enterprise customers designed to scale with their existing and future network infrastructure requirements.

IntelliSite^® provides the industry’s most complete AI-enabled Edge Computing solution. Its applied solutions of Heuristic-Based Monitoring (hBM) and Smart Communities as-a-Service (SCaaS) are utilized by mid-market and enterprise-class customers, partners, and federal, state, and local governments worldwide. IntelliSite’s discovery and assessment methodology, combined with its blue-chip Partner Ecosystem and world-class IntelliCare service and support, delivers the very best outcome-based solutions and sets industry standards for the most reliable edge computing solution for their clients.

About Capital Southwest

Capital Southwest Corporation (Nasdaq: CSWC) is a Dallas, Texas-based, internally managed business development company, with approximately $286 million in net assets as of September 30, 2020. Capital Southwest is a middle market lending firm focused on supporting the acquisition and growth of middle market businesses with $5 to $25 million investments across the capital structure, including first lien, unitranche, second lien, subordinated debt and non-control equity co-investments. As a public company with a permanent capital base, Capital Southwest has the flexibility to be creative in its financing solutions and to invest to support the growth of its portfolio companies over long periods of time.

About DFW Capital Partners

DFW Capital Partners is a private equity investment firm focused on lower middle-market companies. The firm concentrates on service companies, with an emphasis on healthcare and outsourced business and industrial support services. DFW has established a 20+ year track record of success in building leading companies. DFW is headquartered in Teaneck, New Jersey and maintains an office in Chevy Chase, Maryland. For more information visit www.dfwcapital.com.

Forward-Looking Statements

This press release contains historical information and forward-looking statements with respect to the business and investments of Capital Southwest. Forward-looking statements are statements that are not historical statements and can often be identified by words such as “will,” “believe,” “expect” and similar expressions and variations or negatives of these words. These statements are based on management’s current expectations, assumptions and beliefs. They are not guarantees of future results and are subject to numerous risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statement. These risks include risks related to: changes in the markets in which Capital Southwest invests; changes in the financial, capital, and lending markets; regulatory changes; tax treatment and general economic and business conditions; and uncertainties associated with the impact from the COVID-19 pandemic, including its impact on the global and U.S. capital markets and the global and U.S. economy, the length and duration of the COVID-19 outbreak in the United States as well as worldwide and the magnitude of the economic impact of that outbreak; the effect of the COVID-19 pandemic on our business prospects and the operational and financial performance of our portfolio companies, including our ability and their ability to achieve their respective objectives, and the effects of the disruptions caused by the COVID-19 pandemic on our ability to continue to effectively manage our business.

Readers should not place undue reliance on any forward-looking statements and are encouraged to review Capital Southwest’s Annual Report on Form 10-K for the year ended March 31, 2020 and subsequent filings, including the “Risk Factors” sections therein, with the Securities and Exchange Commission for a more complete discussion of the risks and other factors that could affect any forward-looking statements. Except as required by the federal securities laws, Capital Southwest does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.

Investor Relations Contact:

Michael S. Sarner, Chief Financial Officer
214-884-3829

CALGARY, Alberta, Dec. 17, 2020 (GLOBE NEWSWIRE) — Biosenta’s stock closed at 0.75 CAD +0.37 (97.37%). This marked the third day of Alberta’s Province wide Covid-19 lockdown. This is in step with Biosenta’s strategic business plan grow the company and to capture the growing trend for safe, consumer, commercial and industrial disinfectant with anti-microbial compounds. This comes on the eve of Biosenta receiving the patent for Canada.

This is the first step for Biosenta to become a major player in the disinfectant, personal hygiene and anti-microbial categories meeting the market demand for products that are both safe and powerful. Biosenta will continue to implement strategies to grow the company in the next quarter by capitalizing on government and private sector contracts.

About Biosenta Inc.

Biosenta develops and manufactures a range of wet and dry anti-microbial chemical compounds for household and industrial applications using active material, and advanced encapsulated nanotechnology.

Disclaimer

In no way, the CSE has passed upon the contents of this news release and further has neither approved nor disapproved of the contents of this news release. Neither the CSE nor it’s Regulation Services Provider (as such term is defined in the CSE) accepts responsibility for this release’s adequacy or accuracy.

Biosenta Digital channel:

https://www.Biosenta.com

Contact Information:

Am Gill
President and CEO
T: 416-410-2019